Nice study on Thrombocytopenia and Clinical Outcomes in Intracerebral Hemorrhage. Helps further delineate risks for poor outcome after ICH among patients on antiplatelet agents. ahajournals.org/doi/full/10.11…
Over 1/2 of U.S. adults over 45 take antiplatelet agents (APA). ajpmonline.org/article/S0749-…. Studies show disparate results when investigating effect of APA on outcome. doi:10.1161/01.STR.0000231842.32153.74
doi:10.1161/01.STR.0000196991.03618.31
Plt transfusion is common for APA associated ICH, but not show to improve outcomes. PATCH study actually showed worse outcomes in patients who received platelets.
PATCH excluded patients likely to undergo surgery or with sig IVH (likely to require EVD), limiting generalizability to severe-associated ICHs.
Some suggest platelet activity should be checked since this is not affected in all patients onAPAs. Studies taking this approach show conflicting results in which Tx timing may mediate effect. @andynaidech has been a pioneer. rdcu.be/ce9bT
sciencedirect.com/science/articl…
Out meta-analysis showed no benefit to platelet transfusion in APA-associated ICH but was limited by considerable heterogeneity among studies. jns-journal.com/article/S0022-…
Worth noting that in a study of patients on aspirin undergoing crani for tumor resection, there were no increased hemorrhagic complications among pts that continued ASA compared to those who stopped prior to surgery or those that never took ASA. thejns.org/view/journals/…
So maybe need for crani should not be a strict exclusion criteria to future studies?
The current study in Stroke is important because it shows an interaction between APA use and thrombocytopenia on hematoma expansion and outcomes.
Thus, we likely need to be more nuanced in our approach to Plt transfusion in APA-associated ICH. Type of APA (single vs. dual, aspirin vs. clopidogrel, platelet activity/TEG results, comorbidities) might be important.
Excuse the typos. Still working on my tweetorial game.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Nicholas Morris

Nicholas Morris Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @namorrismd

5 Feb
We recently published our first paper sharing validity evidence for the development of neurological emergency simulations for assessment. Are you familiar with forms of validity evidence? If you are an educator, you should be! A thread… rdcu.be/ceMm3
Steven Downing wrote a fantastic review on validity as it pertains to assessment in medical education. Let’s review the highlights! pubmed.ncbi.nlm.nih.gov/14506816/
As Downing states, validity is the sine qua non of assessment. It is approached as a hypothesis. No assessment is “valid” or “invalid” -> assessments have scores with more or less validity evidence to support interpretations.
Read 17 tweets
29 Jan
IV glibenclamide shows promise for reducing cerebral edema and appears to be safe. PO glyburide leads to more hypoglycemia, especially if abnl renal fxn. Smaller, more frequent dosing may help. Kudos to @MikeA_42 for pushing this through to publication. sciencedirect.com/science/articl…
@jessestokum performed work in Dr. Marc Simard's lab demonstrating how SUR1-TRPM4 and AQP4 form a complex that amplifies ion/water osmotic coupling and drives astrocyte swelling after brain injury. @UMDNeurosurgery . onlinelibrary.wiley.com/doi/full/10.10…
The role of Sur1-TRPM4 and AQP4 in the milieu that drives cerebral edema was recently summarized nicely by @MDNeurocritcare fellow Melissa Pergakis.tandfonline.com/doi/abs/10.108…
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!